Matches in Wikidata for { <http://www.wikidata.org/entity/Q92274009> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q92274009 description "clinical trial" @default.
- Q92274009 description "ensayo clínico" @default.
- Q92274009 description "ensayu clínicu" @default.
- Q92274009 description "klinisch onderzoek" @default.
- Q92274009 description "клінічне випробування" @default.
- Q92274009 description "临床试验" @default.
- Q92274009 name "Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy" @default.
- Q92274009 name "Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy" @default.
- Q92274009 type Item @default.
- Q92274009 label "Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy" @default.
- Q92274009 label "Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy" @default.
- Q92274009 prefLabel "Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy" @default.
- Q92274009 prefLabel "Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy" @default.
- Q92274009 P1050 Q92274009-D57A44E0-CA79-4484-9C70-48EC07F6C6FA @default.
- Q92274009 P1132 Q92274009-0D5E46A5-FC54-4C4D-AA6F-667A81C15FA4 @default.
- Q92274009 P1476 Q92274009-83456C31-82D9-49E8-A234-BED09401218A @default.
- Q92274009 P17 Q92274009-D112EA58-9821-4B30-962E-2A7906D9AE74 @default.
- Q92274009 P2899 Q92274009-567B73E9-475F-4474-9FF1-AD8A14566675 @default.
- Q92274009 P3098 Q92274009-19E396AE-CA7D-4BE4-915A-3133E44A2607 @default.
- Q92274009 P31 Q92274009-2758528D-88D9-4863-86F9-7965A25FB978 @default.
- Q92274009 P580 Q92274009-5CA7E5A8-9D63-42F0-9B0B-1554DF0BA96F @default.
- Q92274009 P582 Q92274009-CC24891C-E546-4076-9579-DC43C3569969 @default.
- Q92274009 P6099 Q92274009-BA54AA64-11E3-4355-9A61-755128CFCA6E @default.
- Q92274009 P8005 Q92274009-6C8F469D-1A0F-4E30-A8C7-FFE92DA48530 @default.
- Q92274009 P8363 Q92274009-0AD880FD-1B2A-4F35-9F67-B49519AAB47A @default.
- Q92274009 P859 Q92274009-2742E682-EF68-44E4-BF45-8DD309485268 @default.
- Q92274009 P921 Q92274009-F17458C7-9F9B-479B-BB4F-00AD167E36CA @default.
- Q92274009 P1050 Q229256 @default.
- Q92274009 P1132 "+600" @default.
- Q92274009 P1476 "A Phase 3B Randomized, Double-Blind, Double-Dummy, Active Controlled Multi-Center Study Assessing The Efficacy and Safety of Abrocitinib Compared With Dupilumab in Adult Participants on Background Topical Therapy With Moderate to Severe Atopic Dermatitis" @default.
- Q92274009 P17 Q30 @default.
- Q92274009 P2899 "+18" @default.
- Q92274009 P3098 "NCT04345367" @default.
- Q92274009 P31 Q30612 @default.
- Q92274009 P580 "2020-04-01T00:00:00Z" @default.
- Q92274009 P582 "2021-08-31T00:00:00Z" @default.
- Q92274009 P6099 Q42824827 @default.
- Q92274009 P8005 Q76649614 @default.
- Q92274009 P8363 Q78089383 @default.
- Q92274009 P859 Q206921 @default.
- Q92274009 P921 Q988594 @default.